Straight to the heart: Protecting the patient's heart during chemotherapy.

Cell Stem Cell

Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, VIC, Australia; Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia; The Novo Nordisk Foundation Centre for Stem Cell Medicine (reNEW), Murdoch Children's Research Institute, Parkville, VIC, Australia; Australian Regenerative Medicine Institute, Monash University, Wellington Road, Clayton, VIC, Australia. Electronic address:

Published: December 2024

How do we protect the heart during chemotherapy with the anthracycline drug class? Tackling this question, Liu et al. combined pluripotent stem cell models, CRISPR genetic screens, and molecular modeling to identify indisulam as a potential cardioprotective drug in this issue of Cell Stem Cell.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.stem.2024.10.010DOI Listing

Publication Analysis

Top Keywords

heart chemotherapy
8
stem cell
8
straight heart
4
heart protecting
4
protecting patient's
4
patient's heart
4
chemotherapy protect
4
protect heart
4
chemotherapy anthracycline
4
anthracycline drug
4

Similar Publications

Obstructive shock secondary to an unusual cause: primary cardiac lymphoma.

J Cardiothorac Surg

January 2025

Réanimation Médicale et Chirurgicale, CHU de Guadeloupe, Les Abymes, Guadeloupe, 97139, France.

Background: The medico-surgical management of cardiac tumors when there is a suspicion of malignancy is complex. Moreover, in a critically ill setting, the choice of diagnostic tools seems crucial.

Case Presentation: We present the case of a sixty-four-year-old patient with no prior medical history who was admitted to the intensive care unit with obstructive shock secondary to a right heart mass and pulmonary embolism.

View Article and Find Full Text PDF

Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial.

ESMO Open

January 2025

Uro-Gynecologic Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy. Electronic address:

Background: Ovarian cancer (OvC) constitutes significant management challenges primarily due to its late-stage diagnosis and the development of resistance to chemotherapy. The standard treatment regimen typically includes carboplatin and paclitaxel, with the addition of poly (ADP-ribose) polymerase inhibitors for patients with high-grade serous ovarian cancer (HGSOC) harboring BRCA1/2 mutations. However, the variability in treatment responses suggests the need to investigate factors beyond BRCA1/2 mutations, such as DNA repair mechanisms and epigenetic alterations.

View Article and Find Full Text PDF

Impact of adjuvant trastuzumab therapy and its discontinuation on cardiac function and mortality in patients with early-stage breast cancer: An analysis based on the Japanese Receipt Claim Database.

Breast

December 2024

Department of Clinical Research and Management, Graduate School of Medicine, University of Ryukyus, Japan; Department of Clinical Pharmacology, Faculty of Medicine, University of the Ryukyus, Japan. Electronic address:

Standard trastuzumab therapy can reduce the risk of early recurrence of HER2-positive breast cancer. However, trastuzumab-induced cardiac dysfunction may force the discontinuation of adjuvant trastuzumab therapy. Incidentally, there are still unclear whether or not trastuzumab treatment should be continued in the setting of reduced cardiac function.

View Article and Find Full Text PDF

Background: Coronary stenting operations have become the main option for the treatment of coronary heart disease. Vessel recovery after stenting has emerged as a critical factor in reducing possible complications. In this study, we evaluated the feasibility, safety and efficacy of locally administered intraluminal gene therapy delivered using a specialized infusion balloon catheter.

View Article and Find Full Text PDF

Convergent procedure for long-standing persistent atrial fibrillation in heart failure with reduced ejection fraction.

Arch Cardiovasc Dis

December 2024

Service de cardiologie, hôpital Henri-Mondor, 94000 Créteil, France. Electronic address:

Background: Catheter ablation for atrial fibrillation in patients with heart failure with reduced ejection fraction is associated with a significant reduction in morbimortality. The convergent procedure is a valid ablation option for the treatment of long-standing persistent atrial fibrillation.

Aim: To describe the outcomes of patients with heart failure with reduced ejection fraction and long-standing persistent atrial fibrillation who underwent the convergent procedure.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!